• New organisational capability needs to address major market changes.
• Optimising global strategy and local agility: Updated planning and governance structures.
• Cross-functional leadership and aligned KPIs.
• Digital tools to drive efficiency, effectiveness and feedback.

• How a product’s characteristics or attributes contribute to both individual willingness to pay and “value” from different perspectives (e.g., stakeholder, society).
• The various methodologies through which attribute value can be assessed.
• A real-world case study of how decision-analytic modelling helped a leading medical device company establish the value of a unique product attribute, and by so doing justify higher tender pricing in a key EU market.

• Organisational excellence provides the bridge from strategy to results.
• What are the building blocks of the bridge and what gets missed.
• How should we apply organisational excellence to market access strategy.
• What can we learn from other industries?

• Understanding payer attitudes to optimise business performance.
• What is the optimal reach and frequency of a payer tracker to maximise impact of such an approach.
• How can payer trackers can be utilised to leverage business performance.
• Benefit of payer trackers when sharing information with key internal stakeholders.

Most developed countries apply some form of IRP as a factor in negotiating or regulating domestic pricing. With the emergence of risk sharing agreements and in particular confidential price / volume agreements tied to HTA assessments some experts are suggesting the end of IRP systems in imminent. In contrast, some countries like Canada are placing greater reliance on IRP to lower drug prices.

• Beginnings and Evolution of IRP.
• Overview of approaches to IRP.
• Impact of IRP on product launches and HTA.
• Role of risk-sharing agreements to mitigate impact of IRP.
• Canadian IRP as a case study.

• The revolution has already happened in other sectors: Is health next?
• How is digital technology being deployed along the health value chain?
• How will technology change patient, physician and payer engagement?
• Can technology radically change data collection and analysis in clinical trials and the real world and therefore the assessment of value?

• Current perception of PRO evidence among payers and its influence in decision-making 
• Differences between payer and regulators in assessing PRO evidence

• How similar are HTA agencies in methods and procedures?
• Is there a development towards shared standards?
• What are stakeholders doing to encourage harmonisation/standardisation?
• Is there a need for a European institution to get the job done?